Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 4Differentiated Thyroid Cancer 2Adenoma, Islet Cell 2Tuberous Sclerosis 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Hyperinsulinism 1Growth Hormone-Secreting Pituitary Adenoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Congenital Hyperinsulinism 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Extrapulmonary Neuroendocrine Cancer 1Adenocarcinoma, Follicular 1Acromegaly 1

Interventions

fluorodopa F 18 4Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulinoma × Injections × Endocrine × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡